Cargando…

The Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly: An Evidence-Based Approach

An increasing proportion of patients with advanced non-small cell lung cancer (NSCLC) are over 70 years old, raising unique challenges for treatment decision-making. While these patients are underrepresented in clinical trials, there is an emerging body of evidence associated with this group. The le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dawe, David E., Ellis, Peter Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091126/ https://www.ncbi.nlm.nih.gov/pubmed/25072026 http://dx.doi.org/10.3389/fonc.2014.00178

Ejemplares similares

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
por: Al-Farsi, Abdulaziz, et al.
Publicado: (2014)

Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
por: Melosky, Barbara
Publicado: (2014)

Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
por: Melosky, Barbara
Publicado: (2017)

Role of Radiotherapy in Metastatic Non-Small Cell Lung Cancer
por: Faria, Sergio L.
Publicado: (2014)

The Treatment of Metastatic Non-Small Cell Lung Cancer in a New Era of Personalized Medicine
por: Hirsh, Vera
Publicado: (2015)

Pattern of Treatment Initiation and Outcomes for Patients With Metastatic Non-small Cell Lung Cancer in Ontario
por: Ding, Jerry W, et al.
Publicado: (2022)

Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine
por: Soldera, Sara Victoria, et al.
Publicado: (2017)

The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer
por: Orlov-Slavu, Maria Cristina, et al.
Publicado: (2021)

Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
por: Zhu, Wenyu, et al.
Publicado: (2022)

Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
por: Melosky, Barbara
Publicado: (2017)

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer
por: Bozorgmehr, Farastuk, et al.
Publicado: (2021)

An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)
por: Quinton, Cindy, et al.
Publicado: (2011)

Assessing the robustness of radiomics/deep learning approach in the identification of efficacy of anti–PD-1 treatment in advanced or metastatic non-small cell lung carcinoma patients
por: Ren, Qianqian, et al.
Publicado: (2022)

Metastatic Non-Clear Cell Renal Cell Carcinoma: An Evidence Based Review of Current Treatment Strategies
por: Sankin, Alexander, et al.
Publicado: (2015)

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
por: Melosky, B., et al.
Publicado: (2008)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
por: Morin-Ben Abdallah, Sami, et al.
Publicado: (2017)

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
por: Pacheco, Jose M., et al.
Publicado: (2019)

Current treatments for non-small cell lung cancer
por: Guo, Qianqian, et al.
Publicado: (2022)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer
por: Chicas-Sett, Rodolfo, et al.
Publicado: (2023)

Perioperative outcomes of robotic lobectomy for early-stage non-small cell lung cancer in elderly patients
por: Gallina, Filippo Tommaso, et al.
Publicado: (2022)

Validation of Claims Algorithms for Progression to Metastatic Cancer in Patients with Breast, Non-small Cell Lung, and Colorectal Cancer
por: Nordstrom, Beth L., et al.
Publicado: (2016)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
por: Wang, Hao, et al.
Publicado: (2022)

Association of RANKL and EGFR gene expression with bone metastases in patients with metastatic non-small cell lung cancer
por: Brouns, Anita J.W.M., et al.
Publicado: (2023)

Association of metastatic nodal size with survival in non-surgical non-small cell lung cancer patients: Recommendations for clinical N staging
por: Zhang, Yanan, et al.
Publicado: (2022)

A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
por: Liu, Chang, et al.
Publicado: (2021)

STRA6 Polymorphisms Are Associated With EGFR Mutations in Locally-Advanced and Metastatic Non-Small Cell Lung Cancer Patients
por: Muñiz-Hernández, Saé, et al.
Publicado: (2020)

An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
por: Jiang, Panpan, et al.
Publicado: (2021)

The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer
por: Ramanathan, Siddharth, et al.
Publicado: (2023)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach
por: Chen, Bihong T., et al.
Publicado: (2020)

Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
por: Gan, Yuying, et al.
Publicado: (2021)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer
por: Jeremić, Branislav, et al.
Publicado: (2018)

Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
por: Shi, Xiaoshun, et al.
Publicado: (2021)

Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
por: Ni, Yunfeng, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status
por: Liu, Guoqiang, et al.
Publicado: (2021)

Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer
por: Lewis, Jennifer, et al.
Publicado: (2018)

Dynamic FDG-PET imaging for differentiating metastatic from non-metastatic lymph nodes of lung cancer
por: Wumener, Xieraili, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2gurn0c0s85p43us9floi62qpv